Pages that link to "Q33837017"
The following pages link to Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes (Q33837017):
Displaying 14 items.
- Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review (Q28071386) (← links)
- Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review (Q28079134) (← links)
- SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease (Q33696974) (← links)
- Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents (Q34973750) (← links)
- How much is too much? Outcomes in patients using high-dose insulin glargine (Q36536807) (← links)
- The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities (Q37024780) (← links)
- Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model (Q41922447) (← links)
- Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice (Q42006157) (← links)
- Crosstalk of Hyperglycemia and Dyslipidemia in Diabetic Kidney Disease (Q49982517) (← links)
- The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies (Q58744305) (← links)
- Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials (Q64062502) (← links)
- Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control (Q64294550) (← links)
- Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart (Q85748720) (← links)
- Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats (Q89048416) (← links)